Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA’s Marks Was Frustrated About Slow Completion Of 2021 Comirnaty Review

25 Jan 2023

• By Derrick Gingery

stopwatch — OVRR officials initially proposed completing the Comirnaty BLA review by 15 September 2021. • Source: Shutterstock

Related Content

US COVID-19 Vaccine Booster Plan Also Boosts Pressure On FDA

18 Aug 2021

When Should COVID Vaccines Get Full Approval? US FDA Squeezed By ‘Too Fast’ And ‘Too Slow’ Camps

08 Jul 2021

CBER’s ‘Courageous’ Coronavirus Guidance Strategy May Catch-On

26 Jun 2020

US FDA’s Top Two Vaccine Officials Announce Surprise Retirements

01 Sep 2021

Full Approval Without Some Benefits: FDA Cautions Against Off-Label Use Of Pfizer’s COVID-19 Vaccine For Children, Boosters

24 Aug 2021

Pfizer Vaccine’s Benefit-Risk Assessment In Older Male Adolescents A Close Call Due To Myocarditis

25 Aug 2021

How US FDA Explained The Difference Between Approved And EUA Pfizer/BioNTech COVID-19 Vaccine

25 Jan 2023

US FDA Lowers FY '22 PDUFA Fees Due to Hiring, Attrition Concerns

13 Aug 2021

US FDA ‘Actively Working’ To Fill Vaccine Leadership Positions Ahead Of Next Round Of COVID Reviews

24 Mar 2022

US FDA Biologics Group Emerging From Pandemic Footing – But Not Vaccines

28 Oct 2022

Related Companies

Pfizer Inc.

BioNTech SE

Moderna, Inc.

Additional Topics

United States Coronavirus COVID-19 Vaccines Regulation Approvals BioPharmaceutical

More from Vaccines

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.